Prospects for the Use of ATR Inhibitors to Treat Cancer

Jill M Wagner; Scott H Kaufmann

doi:10.3390/ph3051311

Prospects for the Use of ATR Inhibitors to Treat Cancer

Pharmaceuticals (Basel). 2010 Apr 28;3(5):1311-1334. doi: 10.3390/ph3051311.

Authors

Jill M Wagner¹, Scott H Kaufmann²

Affiliations

¹ Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA. wagner.jill@mayo.edu.
² Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA. kaufmann.scott@mayo.edu.

Abstract

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

Keywords: ATM; ATR; Chk1; Replication checkpoint; chemotherapy.

Publication types

Review